Summary
This prediction ended on 02.07.18 with a price of €20.02. Massive losses of -71.97% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Arsanis | - | - | - | - |
iShares Core DAX® | 1.663% | 6.945% | 18.807% | 17.549% |
iShares Nasdaq 100 | 1.261% | 4.883% | 23.667% | 36.206% |
iShares Nikkei 225® | 0.654% | 10.007% | 15.047% | 9.552% |
iShares S&P 500 | 1.403% | 4.350% | 23.305% | 38.641% |
Comments by stratec for this prediction
In the thread Arsanis diskutieren
Arsanis Pharmaceuticals: A Revolutionary Approach To Infectious Pathogens
- Arsanis (ASNS -2.9%) initiated with Overweight rating and $23 price target by Piper Jaffray. Initiated with Outperform rating by Cowen.
The company is developing monoclonal antibodies directed against bacteria and viruses.
The key R&D program is ASN100, which is directed against 6 cytotoxins critical to Staphylococcus Aureus pathogenesis.
An independent data review committee will conduct an interim analysis in the first half of 2018 to assess the success probability of the trial as designed (a near-term catalyst).
We are initiating coverage on Arsanis stock with a Buy rating and a price target of $35.
(Vom Mitglied beendet)